Generated by AI
Protara Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and rare diseases. Its current pipeline centers on TARA-002, an investigational cell therapy being studied for non-muscle invasive bladder cancer and lymphatic malformations, and intravenous choline chloride, a phospholipid substrate replacement therapy for patients receiving parenteral nutrition. The company’s programs address areas with significant unmet medical need across oncology, rare disease, gastrointestinal, and metabolic care. Protara Therapeutics operates as a research-driven developer of specialty treatments, with its portfolio aimed at advancing targeted options for patient populations that have limited approved alternatives. Headquartered in New York, New York, the company focuses on clinical development and translational science to support its therapeutic candidates.
Website345 Park Avenue South
New York, NY, 10010
United States
The latest articles about TARA.
Company remains on track to report interim results from Phase 2b cohort in 4Q 2026 NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage biotechnology company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it has completed enrollment of the Phase 2b, open-label dose confirmation phase of the THRIVE-3 clinical trial evaluating IV Choline Chloride in patients with intestinal failure who are d
Summary of Oct 16's posts. Generated by AI.
Summary of Feb 24's posts. Generated by AI.
Summary of Feb 24's posts. Generated by AI.
Investors talking about TARA also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.